Our research group focuses on developing and improving antibody therapies for leukemia and lymphoma with the goal of translating the laboratory research into the clinical setting. Dr. John Pagel is the principal investigator of several human clinical trials as well as a clinical research laboratory. In the laboratory we are working to increase the effectiveness of radioimmunotherapy by developing the pretargeted method of delivering radiation to tumor sites. We are also developing therapies, which combine chemical and radioimmunotherapy, with the goal of decreasing toxicities to the patient while increasing the effectiveness of treatment.
Clinical Research Division
1100 Fairview Avenue North / Mailstop D1-100
Seattle Washington, 98109-1024
Principal Investigator: Dr. John M. Pagel
Office: D5-385/ (206) 667-1868